{"generic":"Dacarbazine","drugs":["Dacarbazine","Dtic-Dome"],"mono":[{"id":"3azws0","title":"Generic Names","mono":"Dacarbazine"},{"id":"3azws1","title":"Dosing and Indications","sub":{"0":{"id":"3azws1b4","title":"Adult Dosing","mono":"<ul><li><b>Hodgkin's disease, Second line, in combination with other effective agents:<\/b> 375 mg\/m(2) IV on day 1 (repeat every 15 days) or 150 mg\/m(2)\/day IV for 5 days in combination with other effective drugs (may repeat every 4 weeks)<\/li><li><b>Malignant tumor of Islets of Langerhans:<\/b> Optimal dose and timing of dacarbazine has not been defined in this setting; clinical trials have used a regimen consisting of doxorubicin 60 mg\/m(2) IV on day 1 and dacarbazine 250 mg\/m(2)\/day IV on days 1 through 5; after 4 weeks, streptozocin 500 mg\/m(2) IV and fluorouracil 400 mg\/m(2) IV were each administered daily for 5 days; the cycle was repeated after a total of 8 weeks but the interval between chemotherapy courses was increased to 5 weeks<\/li><li><b>Metastatic malignant melanoma:<\/b> 2 to 4.5 mg\/kg\/day IV for 10 days (may repeat every 4 weeks) or 250 mg\/m(2)\/day IV for 5 days (may repeat every 3 weeks)<\/li><li><b>Sarcoma of soft tissue:<\/b> AD regimen: doxorubicin 60 mg\/m(2) and dacarbazine 1000 mg\/m(2), mixed or administered separately via continuous IV infusion over 4 days, every 21 days if tolerated<\/li><li><b>Sarcoma of soft tissue:<\/b> MAID regimen: doxorubicin 60 mg\/m(2) and dacarbazine 1000 mg\/m(2), mixed or administered separately via continuous IV infusion over 4 days, ifosfamide 6000 mg\/m(2) and mesna 10,000 mg\/m(2) mixed or infused separately over 3 days (ifosfamide) and 4 days (mesna); repeat every 21 days if tolerated<\/li><li><b>Sarcoma of soft tissue:<\/b> MAID regimen: doxorubicin 60 mg\/m(2) and dacarbazine 900 mg\/m(2), mixed and administered through central venous access via continuous IV infusion over 3 days, ifosfamide 7500 mg\/m(2) and mesna 10,000 mg\/m(2) mixed or infused separately through a peripheral line via a continuous IV infusion over 3 days (ifosfamide) and 4 days (mesna); repeat every 21 days if tolerated<\/li><\/ul>"},"3":{"id":"3azws1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Hodgkin's disease, Second line, in combination with other effective agents<\/li><li>Metastatic malignant melanoma<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Carcinoid syndrome<\/li><li>Malignant tumor of Islets of Langerhans<\/li><li>Pheochromocytoma, Malignant<\/li><li>Sarcoma<\/li><li>Sarcoma of soft tissue<\/li><\/ul>"}}},{"id":"3azws2","title":"Black Box Warning","mono":"<b>Intravenous (Powder for Solution)<\/b><br\/>Hemopoietic depression is the most common toxicity with dacarbazine for injection. Hepatic necrosis has also been reported. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals.<br\/>"},{"id":"3azws3","title":"Contraindications\/Warnings","sub":[{"id":"3azws3b9","title":"Contraindications","mono":"hypersensitivity to dacarbazine products<br\/>"},{"id":"3azws3b10","title":"Precautions","mono":"<ul><li>bone marrow depression<\/li><li>extravasation<\/li><li>hepatic dysfunction<\/li><li>renal impairment<\/li><li>use proper procedures for handling and disposal of chemotherapy<\/li><\/ul>"},{"id":"3azws3b11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>D (AUS)<\/li><\/ul>"},{"id":"3azws3b12","title":"Breast Feeding","mono":"<ul><li>WHO: Avoid breastfeeding.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},{"id":"3azws4","title":"Drug Interactions","sub":[{"id":"3azws4b13","title":"Contraindicated","mono":"<ul>Rotavirus Vaccine, Live (established)<\/ul>"},{"id":"3azws4b14","title":"Major","mono":"<ul><li>Adenovirus Vaccine Type 4, Live (established)<\/li><li>Adenovirus Vaccine Type 7, Live (established)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (established)<\/li><li>Influenza Virus Vaccine, Live (established)<\/li><li>Measles Virus Vaccine, Live (established)<\/li><li>Mumps Virus Vaccine, Live (established)<\/li><li>Poliovirus Vaccine, Live (established)<\/li><li>Rubella Virus Vaccine, Live (established)<\/li><li>Smallpox Vaccine (established)<\/li><li>Typhoid Vaccine (established)<\/li><li>Varicella Virus Vaccine (established)<\/li><li>Yellow Fever Vaccine (established)<\/li><\/ul>"},{"id":"3azws4b15","title":"Moderate","mono":"<ul>Aldesleukin (probable)<\/ul>"}]},{"id":"3azws5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension<\/li><li><b>Dermatologic:<\/b>Alopecia<\/li><li><b>Gastrointestinal:<\/b>Loss of appetite, Nausea and vomiting<\/li><li><b>Neurologic:<\/b>Headache, Polyneuropathy<\/li><li><b>Other:<\/b>Influenza-like illness<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Photosensitivity (rare)<\/li><li><b>Hematologic:<\/b>Myelosuppression<\/li><li><b>Hepatic:<\/b>Hepatic necrosis, Hepatic vein thrombosis, Hepatotoxicity<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Cerebral hemorrhage, Seizure<\/li><\/ul>"},{"id":"3azws6","title":"Drug Name Info","sub":{"0":{"id":"3azws6b17","title":"US Trade Names","mono":"Dtic-Dome<br\/>"},"2":{"id":"3azws6b19","title":"Class","mono":"<ul><li>Alkylating Agent<\/li><li>Antineoplastic Agent<\/li><li>Imidazole Carboxamide<\/li><\/ul>"},"3":{"id":"3azws6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"3azws6b21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"3azws7","title":"Mechanism Of Action","mono":"The exact mechanism of action of dacarbazine is unknown. It may inhibit DNA synthesis by acting as a purine analog. The action of dacarbazine may also be due to its action as alkylating agent and its interaction with SH groups.<br\/>"},{"id":"3azws8","title":"Pharmacokinetics","sub":{"1":{"id":"3azws8b24","title":"Distribution","mono":"<ul><li>Vd: 1.49 L\/kg<\/li><li>Protein binding: 0% to 5%<\/li><\/ul>"},"2":{"id":"3azws8b25","title":"Metabolism","mono":"Hepatic; extensive.<br\/>"},"3":{"id":"3azws8b26","title":"Excretion","mono":"Renal: 40% unchanged <br\/>"},"4":{"id":"3azws8b27","title":"Elimination Half Life","mono":"<ul><li>Healthy subjects: 5 hr<\/li><li>Renal and hepatic dysfunction: 7.2 hr<\/li><\/ul>"}}},{"id":"3azws9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>use proper procedures for handling and disposal of dacarbazine<\/li><li>for intravenous use only<\/li><\/ul><\/li><li><b>Intravenous<\/b><br\/><ul><li>reconstitute with Sterile Water for Injection to a concentration of 10 mg\/mL; store at 4 degrees C for 72 hours or normal room conditions for 8 hours<\/li><li>may be further diluted with D5W or NS; store at 4 degrees C for 24 hours or normal room conditions for 8 hours<\/li><li>administer as an IV push (5 to 10 mL) in D5W or NS over at least 1 minute or infuse intravenously in 250 to 500 mL of fluid over 15 to 30 minutes<\/li><li>avoid extravasation as tissue damage and severe pain may occur; hot packs can be applied if local pain, burning, and irritation occurs at the administration site<\/li><\/ul><\/li><\/ul>"},{"id":"3azws10","title":"Monitoring","mono":"<ul><li>evidence of tumor response is indicative of efficacy<\/li><li>white blood cells, red blood cells, and platelets during therapy<\/li><\/ul>"},{"id":"3azws11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Intravenous Powder for Solution: 100 MG, 200 MG<br\/><\/li><li><b>Dtic-Dome<\/b><br\/>Intravenous Powder for Solution: 200 MG<br\/><\/li><\/ul>"},{"id":"3azws12","title":"Toxicology","sub":[{"id":"3azws12b31","title":"Clinical Effects","mono":"<b>DACARBAZINE<\/b><br\/>OVERDOSE: Limited overdose data are available. Overdose effects are likely to be an extension of the adverse effects reported with therapeutic use. ADVERSE EFFECTS: Anorexia, nausea, and vomiting are common. Bone marrow suppression may produce severe leukopenia and thrombocytopenia resulting in death in some cases. Anemia occurs less frequently. Hepatotoxicity (hepatic vein thrombosis, necrosis and veno-occlusive disease) resulting in death has been reported rarely. Anaphylaxis may occur. <br\/>"},{"id":"3azws12b32","title":"Treatment","mono":"<b>DACARBAZINE<\/b><br\/><ul><li>Decontamination: Administered intravenously; ingestion is unlikely.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Nausea and vomiting: May be managed with antiemetics.<\/li><li>Myelosuppression: Administer colony stimulating factor. Filgrastim 5 mcg\/kg\/day subQ or IV over 15 to 30 minutes. Sargramostim: Usual dose is 250 mcg\/m(2)\/day infused IV over 4 hours. Packed red cell and\/or platelet transfusion may be needed in patients with severe thrombocytopenia, anemia, or hemorrhage.<\/li><li>Seizure: IV benzodiazepines, barbiturates.<\/li><li>Anaphylaxis: Mild - antihistamines; Severe - airway management, epinephrine, ECG monitoring, IV fluids<\/li><li>Intrathecal injection: No clinical reports available, information derived from experience with other antineoplastics. Keep patient upright if possible. Immediately drain at least 20 mL CSF; drainage of up to 70 mL has been tolerated in adults.  Follow with CSF exchange (remove serial 20 mL aliquots CSF and replace with equivalent volumes of warmed, preservative free 0.9% saline).  Consult a neurosurgeon for placement of a ventricular catheter and begin ventriculolumbar perfusion (infuse warmed preservative free normal saline through ventricular catheter, drain fluid from lumbar catheter; typical volumes 80 to 150 mL\/hr for 18 to 24 hr, fresh frozen plasma 25 mL\/L or 5% albumin may be added to perfusion fluid to replace CSF protein).  Dexamethasone 4 mg IV every 6 hours to prevent arachnoiditis.<\/li><li>Monitoring of patient: Monitor vital signs, fluid and electrolyte balance, CBC with differential and platelet count, and liver function.<\/li><\/ul>"},{"id":"3azws12b33","title":"Range of Toxicity","mono":"<b>DACARBAZINE<\/b><br\/>TOXICITY - Range of toxicity is not well described. THERAPEUTIC - For metastatic melanoma, 2 to 4.5 mg\/kg\/day for 10 days; may repeat every 4 weeks. An alternative dosing regimen for metastatic melanoma is 250 mg\/m(2)\/day IV for 5 days; may repeat every 3 weeks. Dacarbazine 150 mg\/m(2)\/day for 5 days is used in combination with other drugs as a second line treatment of Hodgkin's disease. Treatment may be repeated every 4 weeks. An alternative dosage regimen for Hodgkin's disease is 375 mg\/m(2)\/day IV on day 1, repeated every 15 days.<br\/>"}]},{"id":"3azws13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid vaccines during therapy due to drug-induced immunosuppression.<\/li><li>Instruct both male and female patients to use reliable contraception, as drug may cause fetal harm if pregnancy occurs during treatment.<\/li><li>Counsel patient that drug may cause infertility in both men and women. Family planning should be discussed with a healthcare professional before initiating drug therapy.<\/li><li>This drug may cause hypotension, alopecia, loss of appetite, nausea, vomiting, headache, polyneuropathy, influenza-like illness, cerebral hemorrhage, or seizure.<\/li><li>Instruct patient to report signs\/symptoms of myelosuppression and hepatotoxicity.<\/li><li>Patient should not drink alcohol while taking this drug.<\/li><\/ul>"}]}